Moshe and Ivet join TWiV to discuss their finding that MIS-C is a consequence of a superantigen in the spike protein of SARS-CoV-2 that causes activation of a skewed population of T cell receptor bearing lymphocytes, leading to hyperinflammation.
On this episode of TWiV, Novavax COVID-19 vaccine demonstrates 90% overall efficacy, preventing an antigenically disruptive change during growth of influenza virus vaccine in chicken eggs, and MIS-C is driven by loss of the gut mucosal barrier.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Jolene Ramsey, Ph.D.